Description
Product details
ST-GLIPTIN 100 Sitagliptin (100mg) Introduction: Diabetes mellitus is a chronic condition characterized by elevated blood sugar levels, necessitating comprehensive management strategies to prevent complications and improve quality of life. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has emerged as a valuable therapeutic option for individuals with type 2 diabetes mellitus (T2DM). ST-GLIPTIN 100, featuring Sitagliptin at a dosage of 100mg, offers a promising avenue for glycemic control. This article explores the features, efficacy, safety profile, and clinical implications of ST-GLIPTIN 100 in the management of T2DM. Understanding Sitagliptin: Sitagliptin exerts its antidiabetic effects by inhibiting the enzyme DPP-4, which degrades incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Sitagliptin prolongs the action of these incretin hormones, leading to increased insulin secretion in a glucose-dependent manner and decreased glucagon secretion, ultimately resulting in improved glycemic control. Key Features of ST-GLIPTIN 100: ST-GLIPTIN 100 is a pharmaceutical formulation containing Sitagliptin at a standardized dosage of 100mg per tablet. This dosage strength provides clinicians with the flexibility to adjust treatment regimens according to individual patient needs, ensuring optimal glycemic control. The formulation of ST-GLIPTIN 100 ensures consistency and reliability in dosing, facilitating effective diabetes management. Efficacy in Glycemic Control: Clinical studies have demonstrated the efficacy of Sitagliptin, including ST-GLIPTIN 100, in improving glycemic control in patients with T2DM. Sitagliptin has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, Sitagliptin is weight-neutral and does not cause hypoglycemia when used as monotherapy. Safety Profile: ST-GLIPTIN 100 exhibits a favorable safety profile, with adverse effects typically mild to moderate in severity. Common side effects may include upper respiratory tract infections, headache, and gastrointestinal symptoms such as nausea or diarrhea, which are often transient and diminish with continued use. Serious adverse events with Sitagliptin are rare, and it is generally well-tolerated by most patients. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/st-gliptin-100-134012
